Novacyt: launches test panel for Covid-19
(CercleFinance.com) - Novacyt announces the launch of SNPsig VariPLEX TM this week, which is its CE-marked polymerase chain reaction (PCR) test panel that is capable of detecting the four currently identified COVID-19 variants of concern (VOC) and the two most biologically significant mutations with a single kit.
The VariPLEX TM panel detects the variants originally identified in the UK, South Africa, Brazil and California, as well as the N501Y and E484K mutations which are now all widespread worldwide.
VariPLEX TM can be deployed on-site at a patient's bedside and can provide results in under two hours.
This provides a rapid alternative or complement to next-generation sequencing, which typically requires up to 14 days of off-site analysis, the group said.
The market definitely likes this news the Novacyt share is up about 4.5% in early trading in Paris on Wednesday.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The VariPLEX TM panel detects the variants originally identified in the UK, South Africa, Brazil and California, as well as the N501Y and E484K mutations which are now all widespread worldwide.
VariPLEX TM can be deployed on-site at a patient's bedside and can provide results in under two hours.
This provides a rapid alternative or complement to next-generation sequencing, which typically requires up to 14 days of off-site analysis, the group said.
The market definitely likes this news the Novacyt share is up about 4.5% in early trading in Paris on Wednesday.
Copyright (c) 2021 CercleFinance.com. All rights reserved.